MedTrace Logo

Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer

NCT00030732 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 319

Last updated 2019-05-15

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without capecitabine in treating pancreatic cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with or without capecitabine in treating patients who have advanced pancreatic cancer.

Conditions

Interventions

DRUG

Gemcitabine + Capecitabine

Gemcitabine + Capecitabine

DRUG

Gemcitabine alone

Gemcitabine alone

Sponsors & Collaborators

  • Central European Cooperative Oncology Group

    collaborator OTHER

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Richard Herrmann, MD · Universitaetsspital-Basel

  • Werner Scheithauer, MD · Allgemeines Krankenhaus - Universitatskliniken

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2004-06-30
Completion
2008-04-30

Countries

  • Austria
  • Israel
  • Italy
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00030732 on ClinicalTrials.gov